Communicate with Supplier? Supplier
Kelly Ms. Kelly
What can I do for you?
+8613375313165
Chat Now
Chat Now Contact Supplier

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsRheumatoid Arthritis RA DrugUpadacitinib Intermediates

Upadacitinib Intermediates (Total 5 Products)

Product categories of Upadacitinib Intermediates, we are specialized manufacturers from China, Upadacitinib Cas 1201187-44-1, Upadacitinib Cas 1428243-26-8 suppliers/factory, wholesale high-quality products of Upadacitinib Intermediate Cas 1201187-44-1 R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
High Quality Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 3R 4S benzyl 3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate 3R 4S 3 2 Bromoacetyl 4 ethyl 1 pyrrolidinecarboxylicacidphenylmethylester intermediateofabt594 3R 4S benzyl3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate...
Pharmaceutical Raw Material Cas 1201187-44-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name tert butyl 5 tosyl 5H pyrrolo 2 3 b pyrazin 2 ylcarbamate tert butylN 5 4 methylbenzenesulfonyl 5H pyrrolo 2 3 b pyrazin 2 yl carbamate tert butChemicalbookyl 5 p toluenesulfonyl 5H pyrrolo 2 3 b pyrazin 2 yl carbamate...
Pharmaceutical Raw Material Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 3R 4S benzyl 3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate 3R 4S 3 2 Bromoacetyl 4 ethyl 1 pyrrolidinecarboxylicacidphenylmethylester intermediateofabt594 3R 4S benzyl3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate...
Upadacitinib Intermediate Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 3R 4S benzyl 3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate 3R 4S 3 2 Bromoacetyl 4 ethyl 1 pyrrolidinecarboxylicacidphenylmethylester intermediateofabt594 3R 4S benzyl3 2 bromoacetyl 4 ethylpyrrolidine 1 carboxylate...
Upadacitinib Intermediate Cas 1201187-44-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name tert butyl 5 tosyl 5H pyrrolo 2 3 b pyrazin 2 ylcarbamate tert butylN 5 4 methylbenzenesulfonyl 5H pyrrolo 2 3 b pyrazin 2 yl carbamate tert butChemicalbookyl 5 p toluenesulfonyl 5H pyrrolo 2 3 b pyrazin 2 yl carbamate...

China Upadacitinib Intermediates Suppliers

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ™ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.

Home

Product

Whatsapp

About Us

Inquiry